Maitreya Medicare H1 FY27: OPM up 254 bps, sales flat

What the filing says and why it matters

Maitreya Medicare Limited filed its consolidated financial results for H1 FY27 on 22 Oct 2026. The board approved standalone and consolidated results for the half year ended 30 September 2026. The headline takeaway was margin improvement, even as reported sales were broadly flat year-on-year. Operating margin expanded by 254 basis points compared with the same period last year, reflecting a stronger operating profit. Separately, the company disclosed that it has fully deployed the IPO proceeds of ₹14.89 crore, with no unutilised balance remaining. One of the key uses of the issue proceeds was a ₹7.50 crore deployment into its subsidiary, Maitreya Hospital Pvt Ltd, for expansion at Valsad.

H1 FY27 consolidated snapshot

For the half year ended September 2026, Maitreya Medicare reported sales of ₹23.7 crore. This was down 0.1% year-on-year, indicating that topline growth was largely unchanged compared with the same half last year. Sequentially, the filing indicated sales were up 11.9% versus the previous half. Operating profit rose sharply on a year-on-year basis, and the company swung back to operating profitability compared with the preceding half year. Operating margin also moved into a clearly positive range versus the prior half.

Operating profit swing drives margin expansion

The operating profit for H1 FY27 came in at ₹1.6 crore. A year earlier, operating profit was ₹1.0 crore, and the previous half (March 2026) showed an operating loss of ₹1.5 crore. This swing is visible in the operating profit margin (OPM) figures. OPM for September 2026 was 6.9%, compared with 4.4% in September 2025 and -7.0% in March 2026. The company’s disclosure highlighted a 254 bps year-on-year expansion in operating margin. Versus the previous half, OPM improved by 1,397 bps.

Other income movement

Other income for the half year ended September 2026 was ₹0.3 crore. This was up 49.8% year-on-year versus ₹0.2 crore in September 2025. However, it was down 54.7% versus ₹0.8 crore in March 2026. The mixed movement in other income means the period’s profitability picture is still driven primarily by the turnaround in operating performance rather than a consistent rise in non-operating items.

IPO proceeds fully utilised: what the company disclosed

Alongside the results, an “AI read of the filing” summary stated that Maitreya Medicare has fully utilised its IPO proceeds. The amount disclosed was ₹14.89 crore (also shown as ₹148,912 thousand), with zero unutilised balance. The filing summary also indicated that ₹7.50 crore (₹75,000 thousand) was deployed into subsidiary Maitreya Hospital Pvt Ltd for Valsad expansion. This is a material disclosure because it clarifies where the issue proceeds went and whether any funds remain pending deployment.

Board meeting, results timeline, and compliance updates

The company informed the exchange about a board meeting held on 22-Oct-2026 to consider and approve unaudited financial results for the half year ended September 2026. The filing time listed was 22 Oct 2026, 17:45. In the run-up to results, the company also announced that its trading window would be closed from 1 October 2026 until 48 hours after the H1 FY2026-27 results. Separately, the company held its 7th AGM on 21 September 2026, where shareholders approved the financial statements and reappointed the Whole-time Director.

Market snapshot around the results event

The corporate action table in the provided data listed a “Quarterly Result Announcement” dated 22 Oct 2026. The last traded price (LTP) at announcement was ₹125.75, while the LTP at record day was listed as ₹134.75. While this is not a full price chart, it gives a reference point for how the stock was trading around the disclosure window. Investors typically track these changes alongside operating performance, especially when margins move significantly.

Key numbers at a glance

FY2026 context: earnings turned negative

The same data set also referenced full year 2026 earnings, showing a loss per share of ₹3.64 versus a profit per share of ₹2.76 in FY 2025. Revenue for FY 2026 was listed at ₹45.84 crore, down 1.8% from FY 2025 (converted from ₹458.4 million). Net loss for FY 2026 was ₹2.47 crore, compared with a profit in FY 2025 (converted from ₹24.7 million). This context matters because the H1 FY27 margin improvement comes after a year in which profitability had turned negative.

What investors may track next

Based on the disclosures provided, the most immediate items to monitor are the trend in operating margin and whether the operating profit recovery sustains in subsequent periods. Investors may also watch for updates on the Valsad expansion, given the stated ₹7.50 crore deployment into the subsidiary. The company’s governance and compliance timeline, including trading window closures and board approvals, will remain relevant around future results dates. Any further disclosures in subsequent filings will help clarify whether flat sales in H1 FY27 was a one-off or part of a broader demand pattern.

Conclusion

Maitreya Medicare’s H1 FY27 consolidated filing showed flat sales at ₹23.7 crore but a clear operating turnaround, with OPM rising to 6.9% and improving 254 bps year-on-year. The company also disclosed full utilisation of ₹14.89 crore in IPO proceeds, including ₹7.50 crore for subsidiary-led Valsad expansion. The next meaningful updates are likely to come through subsequent periodic results filings and any project-related announcements tied to the expansion spending.